Assembly Biosciences, Inc. (ASMB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Assembly Biosciences, Inc. (ASMB) Healthcare & Pipeline Overview

Assembly Biosciences, Inc. is a clinical-stage biotechnology firm specializing in HBV therapeutics, with Vebicorvir advancing through clinical trials. The company differentiates itself through strategic collaborations and a pipeline targeting chronic HBV infection, operating within the competitive biotechnology landscape.

What Is the Investment Thesis for ASMB?

Assembly Biosciences presents a focused investment opportunity within the biotechnology sector, driven by its pipeline of HBV therapeutics. The company's lead candidate, Vebicorvir, having completed Phase 2 trials, represents a near-term value driver. Strategic collaborations with BeiGene, Arbutus, and Antios offer potential synergy and accelerated development of combination therapies. A key risk lies in the inherent uncertainty of clinical trials and regulatory approvals. The company's market capitalization of $604M reflects both the potential and the risks associated with its clinical-stage status. Successful advancement of its pipeline could significantly increase shareholder value, while clinical setbacks could negatively impact the stock. The company's negative profit margin of -9.0% underscores its reliance on future product revenue.

Based on FMP financials and quantitative analysis

ASMB Key Highlights

Market capitalization of $604M reflects investor valuation of Assembly Biosciences' pipeline and potential.

• Gross margin of 77.2% indicates strong potential profitability upon commercialization of products.
• Beta of 1.16 suggests Assembly Biosciences' stock is slightly more volatile than the overall market.
• Vebicorvir's completion of Phase 2 clinical trials marks a significant milestone in the company's development pipeline.
• Strategic collaborations with BeiGene, Arbutus, and Antios provide opportunities for synergistic drug development and expanded market reach.

Who Are ASMB's Competitors?

ASMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ASMB's Key Strengths?

Promising lead product candidate, Vebicorvir, in Phase 2 clinical trials.

• Strategic collaborations with BeiGene, Arbutus, and Antios.
• Strong intellectual property portfolio in the HBV therapeutic area.
• Experienced management team with expertise in drug development.

What Are ASMB's Weaknesses?

Clinical-stage company with no currently marketed products.

• High research and development costs.
• Dependence on successful clinical trial outcomes and regulatory approvals.
• Negative profit margin and reliance on future product revenue.

What Could Drive ASMB Stock Higher?

Announcement of Phase 3 clinical trial results for Vebicorvir.

• Initiation of clinical trials for ABI-H3733.
• Progression of ABI-4334 through preclinical development.
• Expansion of strategic collaborations and licensing agreements.

What Are the Key Risks for ASMB?

Negative return on equity (-4.2%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Rich valuation — a P/E of 55.38 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Clinical trial failures or delays for Vebicorvir and other drug candidates.
• Regulatory hurdles and competition from other HBV therapies.
• High research and development costs.
• Dependence on successful fundraising and investor support.

What Are the Growth Opportunities for ASMB?

• Advancement of Vebicorvir through Phase 3 clinical trials: Successful completion and positive results in Phase 3 trials for Vebicorvir could lead to regulatory approval and commercialization, capturing a significant share of the HBV therapeutics market. Timeline: Anticipated completion of Phase 3 trials within the next 2-3 years.
• Development of ABI-H3733: Continued development of ABI-H3733, currently in Phase 1a clinical study, represents a growth opportunity by expanding the company's pipeline with a novel therapeutic candidate. Positive results in early-stage trials could attract further investment and partnerships. The market for new HBV therapies is driven by the need for improved efficacy and safety profiles. Timeline: Progression through clinical trials over the next 3-5 years.
• Expansion of strategic collaborations: Forming new strategic collaborations with pharmaceutical companies and research institutions can provide access to new technologies, funding, and expertise. These collaborations can accelerate the development and commercialization of Assembly Biosciences' pipeline. The biotechnology industry is characterized by collaborative partnerships to share resources and mitigate risks. Timeline: Ongoing, with potential for new collaborations in the near term.
• Preclinical Development of ABI-4334: The continued preclinical development of ABI-4334 offers a future growth opportunity by expanding the company's HBV therapeutic options. Successful preclinical results could lead to clinical trials and potential market entry. The market for novel HBV treatments continues to grow, creating a need for innovative solutions. Timeline: Preclinical development ongoing, with potential clinical trials in 2-3 years.
• Triple Combination Therapy Evaluation: The collaboration with BeiGene, Arbutus Biopharma Corporation, and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection provides a growth opportunity through synergistic drug development. This approach could lead to more effective treatments and a larger market share. The combination therapy market is growing as it addresses complex diseases with multiple mechanisms. Timeline: Clinical trial results expected within the next 1-2 years.

What Threats Does ASMB Face?

• Clinical trial failures or delays.
• Regulatory hurdles and competition from other HBV therapies.
• Patent expiration and generic competition.
• Economic downturn and reduced healthcare spending.

What Are ASMB's Competitive Advantages?

• Proprietary drug candidates and intellectual property in the HBV therapeutic area.
• Clinical trial data demonstrating the safety and efficacy of its drug candidates.
• Strategic collaborations with leading pharmaceutical companies and research institutions.
• Expertise in HBV drug development and regulatory approval processes.

What Does ASMB Do?

Assembly Biosciences, Inc., founded in 2005 and headquartered in South San Francisco, California, is a clinical-stage biotechnology company dedicated to discovering and developing innovative therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Originally incorporated as Ventrus Biosciences, Inc., the company rebranded in June 2014 to reflect its focused approach on HBV therapeutics. The company's lead product candidate, Vebicorvir, has completed Phase 2 clinical trials, demonstrating the company's commitment to advancing potential treatments for patients with chronic HBV infection. In addition to Vebicorvir, Assembly Biosciences is also developing ABI-H3733, which has completed Phase 1a clinical study, and ABI-4334, currently in pre-clinical trials. These programs highlight the company's multi-faceted approach to addressing HBV infection. Assembly Biosciences strategically collaborates with other companies, including BeiGene, Ltd., Arbutus Biopharma Corporation, and Antios Therapeutics, Inc., to evaluate triple combination treatments for chronic HBV. The company also has strategic license agreements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC, further expanding its research and development capabilities. Assembly Biosciences operates primarily in the United States, focusing on addressing the unmet medical needs of individuals affected by HBV infection.

What Products and Services Does ASMB Offer?

• Discovers and develops therapeutic candidates for hepatitis B virus (HBV) infection.
• Focuses on developing treatments for patients with chronic HBV infection.
• Advances Vebicorvir through clinical trials.
• Develops ABI-H3733 and ABI-4334 as potential HBV therapies.
• Collaborates with other companies to evaluate combination treatments.
• Seeks strategic license agreements to expand research and development capabilities.
• Aims to address unmet medical needs in the HBV market.

How Does ASMB Make Money?

• Develops and patents novel therapeutic candidates for HBV infection.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
• Collaborates with other companies to share resources and accelerate drug development.
• Seeks regulatory approval from the FDA to commercialize its products.
• Generates revenue through product sales and licensing agreements.

What Industry Does ASMB Operate In?

Assembly Biosciences operates within the biotechnology industry, specifically targeting the hepatitis B virus (HBV) therapeutics market. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The HBV market is driven by the need for more effective and durable treatments for chronic HBV infection. Assembly Biosciences competes with larger pharmaceutical companies and other biotechnology firms developing HBV therapies. The company's success depends on its ability to develop and commercialize innovative therapies that address unmet medical needs in the HBV market.

Who Are ASMB's Key Customers?

• Patients with chronic hepatitis B virus (HBV) infection.
• Hospitals and clinics that treat HBV patients.
• Pharmaceutical companies that may license or acquire Assembly Biosciences' products.
• Healthcare providers who prescribe HBV therapies.

Assembly Biosciences, Inc. Financial Trajectory

Assembly Biosciences, Inc. (ASMB) reported $13.4M in revenue for Q2 FY2026, reflecting 62.8% growth compared to the prior quarter. The company recorded a net loss of $3.9M, with diluted EPS of $-0.20. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ASMB averaged $0.01 in diluted EPS.

Company Profile

Assembly Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Jason A. Okazaki. ASMB has traded publicly since 2010.

How Assembly Biosciences, Inc. Is Valued

Assembly Biosciences, Inc. carries a market capitalization of $604M, placing it in the small-cap category. Analyst price targets span from $50.00 to $53.00, with a consensus of $51.67. At the current price of $30.46, that implies approximately 70% upside potential. Relative to its peer group, ASMB's quantitative score of 39/100 is below the peer average of 83/100.

Return on equity for Assembly Biosciences, Inc. stands at -4.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.7%, the inverse of the P/E and a quick read on earnings relative to price.

Assembly Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 13.27 places it in the safe zone, indicating low near-term bankruptcy risk.

Assembly Biosciences, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 76.8% above estimates on average.

Over the past six months, Assembly Biosciences, Inc. insiders filed 22 SEC Form 4 transactions — 5 sales and 17 purchases. On net that is roughly 794K shares acquired (about $13.6M) — insiders putting money in tends to read as conviction.

ASMB Financials

ASMB Latest News

ASMB Analyst Consensus

ASMB MoonshotScore

What Investors Ask About Assembly Biosciences, Inc. (ASMB) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources